Faruqi & Faruqi & Aldeyra Therapeutics
2 shared events · Importance 3 · Last updated Jun 03, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
Faruqi & Faruqi: Faruqi & Faruqi is investigating potential claims against Aldeyra Therapeutics and reminding investors of the deadline to seek the role of lead plaintiff in the federal securities class action.
Aldeyra Therapeutics: Aldeyra Therapeutics is the primary defendant in multiple class action lawsuits filed by various law firms, alleging that the company made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap. The company's stock price fell significantly after the United States — Food and Drug Administration issued a Complete Response Letter for reproxalap.
Apr 24, 2026 · 80 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Faruqi & Faruqi and Aldeyra Therapeutics interact across events, view sentiment trends, and discover connected entities.
Open Dashboard